T. Rowe Price Small-Mid Cap ETF
TMSL - ETF AI Analysis
Top Page
T. Rowe Price Small-Mid Cap ETF (TMSL)
TMSL, the T. Rowe Price Small-Mid Cap ETF, earns a solid overall rating driven by several strong core holdings with healthy financial performance and positive outlooks. Standout positions like Permian Resources and APi Group support the fund’s quality through robust growth, strategic flexibility, and solid cash flow, while weaker names such as Charles River Labs and Guardant Health, which face profitability and valuation challenges, modestly weigh on the rating. The main risk factor is exposure to companies with cash flow and leverage concerns, which could increase volatility if business conditions worsen.
TMSL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 3.30B
- Region
- North America
- Expense Ratio
- 0.55%
- Beta
- 0.98
- Issuer
- T. Rowe Price
- Inception Date
- Jun 15, 2023
- Dividend Yield
- 0.48%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TMSL Summary
T. Rowe Price Small-Mid Cap ETF (TMSL) is an actively managed fund that focuses on smaller and mid-sized U.S. companies, following an “extended market” theme beyond the big, well-known large caps. It spreads investments across many sectors, including technology, health care, financials, and industrials. Well-known names in the fund include Stanley Black & Decker and Tenet Healthcare. Investors might consider TMSL for growth potential and added diversification, since smaller companies can expand faster than large ones. However, these stocks can be more volatile, so the ETF’s value can go up and down more sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.55%, which means you’ll pay about $5.50 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because TMSL is actively managed, so you’re paying more for professional stock selection in small- and mid-cap companies.
What would affect this ETF?
This U.S.-focused ETF could benefit if the economy stays healthy, interest rates eventually ease, and innovation in areas like technology, health care, and industrials drives growth for smaller companies. On the downside, higher-for-longer interest rates, an economic slowdown that hits small and mid-sized businesses harder, or sector-specific challenges in financials, energy, and real estate could weigh on the fund’s future performance.
TMSL Top 10 Holdings
TMSL leans into U.S. small- and mid-cap growth stories, with a mix of health care, energy, and industrial names steering the ship. Charles River Labs and Guardant Health have been rising sharply, giving the fund a strong health care tailwind, while Permian Resources adds punch from the energy patch. Reliance Steel and Stanley Black & Decker are steady industrial workhorses, helping smooth out volatility. Popular and Corpay are more mixed, occasionally losing steam, but overall the fund’s diversified lineup keeps any single laggard from dragging performance too far off course.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 THC | Tenet Healthcare | 1.27% | $41.72M | $23.10B | 47.73% | 74Outperform |
 BPOP | Popular | 1.09% | $35.95M | $9.93B | 37.82% | 77Outperform |
 SWK | Stanley Black & Decker | 1.05% | $34.35M | $17.31B | 70.98% | 68Neutral |
 CPAY | Corpay Inc | 1.02% | $33.60M | $29.40B | 58.93% | 75Outperform |
 PR | Permian Resources | 0.96% | $31.44M | $18.22B | 64.84% | 81Outperform |
 RS | Reliance Steel | 0.92% | $30.20M | $21.76B | 58.96% | 74Outperform |
 AXS | Axis Capital | 0.85% | $28.00M | $7.74B | 7.80% | 70Neutral |
 MIDD | The Middleby | 0.88% | $29.02M | $6.25B | 10.26% | 61Neutral |
 CRL | Charles River Labs | 0.90% | $29.47M | $16.57B | 97.52% | 60Neutral |
 RL | Ralph Lauren | 0.84% | $27.52M | $23.79B | 18.06% | 78Outperform |
TMSL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMSL, the sentiment is Positive. The current price of 42.65 is above the 20-day moving average (MA) of 41.56, above the 50-day MA of 41.48, and above the 200-day MA of 40.90, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 58.67 is Neutral, neither overbought nor oversold. The STOCH value of 90.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TMSL.
TMSL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TMSL | $42.65 | $44.00(3.17% Upside) | $3.30B | 0.55% | 68Neutral |
 FELC | $42.87 | $51.78(20.77% Upside) | $8.91B | 0.18% | 73Outperform |
 FMDE | $42.24 | $48.76(15.45% Upside) | $8.83B | 0.23% | 69Neutral |
 CGMM | $32.09 | $38.60(20.28% Upside) | $3.67B | 0.51% | 66Neutral |
 JMEE | $75.65 | $90.10(19.10% Upside) | $2.95B | 0.24% | 66Neutral |
 SMIG | $32.82 | $36.78(12.07% Upside) | $1.50B | 0.60% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TMSL | T. Rowe Price Small-Mid Cap ETF | 42.65 | 8.30 | 24.17% | |
| FELC | Fidelity Enhanced Large Cap Core ETF | 42.87 | 5.68 | 15.28% | |
| FMDE | Fidelity Enhanced Mid Cap ETF | 42.24 | 7.07 | 20.11% | |
| CGMM | Capital Group U.S. Small and Mid Cap ETF | 32.09 | 4.48 | 16.23% | |
| JMEE | JPMorgan Market Expansion Enhanced Equity ETF | 75.65 | 13.54 | 21.80% | |
| SMIG | AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF | 32.82 | 4.96 | 17.80% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.